HC Wainwright Has Negative Outlook for SGMT FY2027 Earnings

Sagimet Biosciences Inc. (NASDAQ:SGMT) – Analysts at HC Wainwright dropped their FY2027 earnings per share (EPS) estimates for Sagimet Biosciences in a report issued on Wednesday, March 11th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings of ($2.62) per share for the year, down from their previous forecast of ($2.49). HC Wainwright has a “Buy” rating and a $29.00 price target on the stock. The consensus estimate for Sagimet Biosciences’ current full-year earnings is ($1.60) per share. HC Wainwright also issued estimates for Sagimet Biosciences’ FY2028 earnings at ($3.22) EPS and FY2029 earnings at ($1.87) EPS.

Sagimet Biosciences (NASDAQ:SGMT) last released its earnings results on Wednesday, March 11th. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.14.

Other equities analysts have also recently issued reports about the company. Guggenheim began coverage on Sagimet Biosciences in a research note on Tuesday, February 3rd. They set a “buy” rating and a $27.00 price objective on the stock. Barclays began coverage on shares of Sagimet Biosciences in a report on Tuesday, January 27th. They set an “equal weight” rating and a $8.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Sagimet Biosciences in a research report on Thursday, January 22nd. Finally, Wall Street Zen raised shares of Sagimet Biosciences from a “sell” rating to a “hold” rating in a report on Saturday. Seven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $26.00.

Sagimet Biosciences Trading Down 2.4%

Shares of NASDAQ SGMT opened at $5.21 on Monday. The company has a market capitalization of $169.43 million, a price-to-earnings ratio of -3.32 and a beta of 3.35. Sagimet Biosciences has a twelve month low of $1.73 and a twelve month high of $11.41. The business has a 50 day simple moving average of $5.73 and a 200-day simple moving average of $6.61.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. raised its stake in shares of Sagimet Biosciences by 4.3% during the third quarter. Vanguard Group Inc. now owns 1,203,231 shares of the company’s stock valued at $8,254,000 after purchasing an additional 49,375 shares in the last quarter. Affinity Asset Advisors LLC grew its position in Sagimet Biosciences by 228.1% in the 4th quarter. Affinity Asset Advisors LLC now owns 1,148,245 shares of the company’s stock valued at $6,798,000 after buying an additional 798,245 shares in the last quarter. Marshall Wace LLP bought a new position in Sagimet Biosciences in the 4th quarter valued at about $4,620,000. Millennium Management LLC increased its stake in Sagimet Biosciences by 6,484.7% during the 3rd quarter. Millennium Management LLC now owns 776,377 shares of the company’s stock valued at $5,326,000 after buying an additional 788,537 shares during the period. Finally, Schonfeld Strategic Advisors LLC increased its stake in Sagimet Biosciences by 462.4% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 523,774 shares of the company’s stock valued at $3,593,000 after buying an additional 430,644 shares during the period. Institutional investors own 87.86% of the company’s stock.

Insider Transactions at Sagimet Biosciences

In related news, CEO David Happel sold 12,101 shares of the firm’s stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $5.36, for a total value of $64,861.36. Following the sale, the chief executive officer directly owned 677,621 shares in the company, valued at $3,632,048.56. This trade represents a 1.75% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 14.70% of the stock is owned by company insiders.

Sagimet Biosciences Company Profile

Sagimet Biosciences (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company’s lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101’s potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.